An interventional study of Cranberry beverage and Placebo beverage in Overweight/Obesity, Metabolic Syndrome and Insulin Resistance, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Laval University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Obesity by Laval University — 11 open to participants now, 12 under way, none of them phase 3. Obesity · Laval University.
Among the 31 studies in Obesity by Laval University, this one is the 14th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 30th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →11 of the 31 studies in Obesity by Laval University are open now, in 1 country. Recruiting first, the newest first:
Laval University · Sites in Canada
Ages 18–70
Laval University · Sites in Canada
Ages 18–65
Laval University · Sites in Canada
Ages 18–45 · Healthy volunteers
Laval University · Sites in Canada
Ages 18–65
Laval University · Sites in Canada
Ages 18–60
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 25 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 73 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 94 across the 24 interventional studies, 60 across the 7 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
3 of the studies in Obesity by Laval University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07460856Laval UniversityEffects of Cranberry on Gut and Metabolic Health | 2026-12 |
| NCT05242835Laval UniversityManagement of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery | 2027-01 |
| NCT07201870Laval UniversityDigital Preparation for Bariatric Surgery: Feasability Pilot Trial | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Obesity by Laval University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.
The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.
This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 73 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Cranberry beverage
Dietary Supplement: Placebo beverage
Daily consumption of 240 ml of cranberry beverage for 12 weeks.
Daily consumption of 240 ml of placebo beverage for 12 weeks.
Change in glucose homeostasis
Assessment of glucose concentrations during a 3-hour oral glucose tolerance test (OGTT)
Time frame: Pre and post each treatment (12 week/each)
Change in insulin secretion
Assessment of insulin a concentrations during a 3-hour oral glucose tolerance test (OGTT)
Time frame: Pre and post each treatment (12 week/each)
Change in insulin secretion
Assessment of C-Peptide concentrations during a 3-hour oral glucose tolerance test (OGTT)
Time frame: Pre and post each treatment (12 week/each)
Change in lipid profile
Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol
Time frame: Pre and post each treatment (12 week/each)
Change in other measures of glucose homeostasis
Assessment of glycated hemoglobin (HbA1c)
Time frame: Pre and post each treatment (12 week/each)
Change in blood pressure
Assessment of systolic and diastolic blood pressure
Time frame: Pre and post each treatment (12 week/each)
Change in chronic inflammation
Assessment of plasma high sensitive C-Reactive Protein (hs-CRP) concentrations
Time frame: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Assessment of body mass index (BMI) using weight and height. These two measurements will be combined to calculate BMI in kg/m2
Time frame: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Assessment of waist circumference
Time frame: Pre and post each treatment (12 week/each)
Change in body composition
Assessment of changes in lean mass, fat mass and visceral fat mass (all in grams) using body composition by Dual X-ray Absorptiometry scan
Time frame: Pre and post each treatment (12 week/each)
Change in gut microbiota
Assessment of global variation of the fecal microbiota
Time frame: Pre and post each treatment (12 week/each)
Change in gut microbiota function
Assessment of short-chain fatty acid (SCFA) in feces
Time frame: Pre and post each treatment (12 week/each)
Change in fat accumulation in the liver
Evaluation of fat accumulation using magnetic resonance imaging (MRI) in a subgroup of women only.
Time frame: Pre and post each treatment (12 week/each)
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 17 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.